Oncotarget

Research Papers:

18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer

Jingyi Cheng, Yujie Wang, Miao Mo, Xiao Bao, Yingjian Zhang, Guangyu Liu, Jun Zhang and Daoying Geng _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:29388-29395. https://doi.org/10.18632/oncotarget.5001

Metrics: PDF 882 views  |   HTML 1222 views  |   ?  


Abstract

Jingyi Cheng1,*, Yujie Wang2,*, Miao Mo3, Xiao Bao4, Yingjian Zhang4, Guangyu Liu2, Jun Zhang1, Daoying Geng1

1Department of Radiology, Huashan Hospital, Fudan University, Shanghai, P.R. China

2Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China

3Clinical Statistics Center, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China

4Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University Shanghai, P.R. China

*These authors have contributed equally to this work

Correspondence to:

Daoying Geng, e-mail: daoyinggeng@163.com

Jun Zhang, e-mail: zhj81828@163.com

Keywords: breast cancer, neoadjuvant therapy, trastuzumab, FDG PET/CT

Received: May 18, 2015     Accepted: August 11, 2015     Published: August 21, 2015

ABSTRACT

The aim of this prospective study was to assess the ability of 18F-fluorodeoxyglucose (18FDG) positron emission tomography/computed tomography (PET/CT) scanning to predict pathological complete response (pCR) in breast cancer, and to investigate whether timing of the scan and trastuzumab treatment influence the accuracy of pCR prediction in human epidermal growth factor receptor 2 (HER2) positive breast cancer patients. We treated 81 locally advanced breast cancer patients with four cycles of neoadjuvant chemotherapy (NAC). HER2-negative breast cancer patients received NAC alone, while HER2-positive breast cancer patients received NAC plus trastuzumab. 18FDG PET/CT scans were scheduled at baseline and after the second cycle of NAC. Axillary lymph node (ALN) dissection was performed after the last cycle of neoadjuvant therapy. Relative changes in standardized uptake values (SUV) between the two PET/CT scans (ΔSUV) in primary tumors and ALN metastases were calculated. There were 75 patients with 150 PET/CT scans in the final analysis, including 41 HER2-negative and 34 HER2-positive cases. In the HER2-negative group, the ΔSUV predicted overall and ALN pCR; the receiver operating characteristics-areas under curve (ROC-AUC) were 0.87 and 0.80 (P = 0.0014 and 0.031, respectively) and the negative predictive values were 94% and 89% respectively. However, in the HER2-positive group, ΔSUV could predict neither overall nor ALN pCR; the ROC-AUCs were only 0.56 and 0.53, with P = 0.53 and 0.84, respectively. Hence, the ΔSUV after two cycles of neoadjuvant therapy could predict pCR in HER2-negative patients treated with NAC alone, but not in HER2-positive patients treated with NAC plus trastuzumab.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5001